Acute Sideroblastic Anemia in Active Systemic Lupus Erythematosus

Jiménez-Balderas, Francisco Javier; Morales-Polanco, M R; Gutiérrez, Laura

doi:10.1177/096120339400300305

Cited by 14 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…congenital dyserythropoietic anemias, thalassemias, congenital dyserythropoietic porphyria 1 or hereditary sideroblastic anemia 2 or acquired MDS, as well as secondary disorders. Secondary myelodysplasia-like changes are found in severe illness, 3 after exposure to drugs, 4 toxins, 5,6 autoimmune diseases, 7 vitamin B12, folate and copper deficiency, 8,9 parvovirus B19 infection 10 or excessive alcohol intake. 11,12 They are neither neoplastic nor pre-leukemic.…”

Section: Introductionmentioning

confidence: 99%

Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors

Parmentier¹,

Schetelig²,

Lorenz³

et al. 2011

Haematologica

View full text Add to dashboard Cite

BackgroundAccording to WHO 2008 guidelines, the required percentage of cells manifesting dysplasia in the bone marrow to qualify as significant is 10% or over in one or more hematopoietic cell lineages, but this threshold is controversial. No 'normal' values have been established. Therefore, we investigated dyshematopoiesis in bone marrow aspirate squash preparations of 120 healthy bone marrow donors. Design and MethodsBone marrow squash slides of 120 healthy unrelated bone marrow donors were examined independently by 4 experienced morphologists. Samples were taken from the first aspiration during the harvest. Bone marrow preparation and assessment were performed according to WHO recommendations and ICSH guidelines. ResultsMore than 10% dysmyelopoiesis could be detected in 46% of bone marrow aspirate squash preparations with 26% in 2 or more cell lineages and 7% in 3 cell lineages in healthy bone marrow donors. Donors under the age of 30 years exhibited more dysgranulopoietic changes and dysmegakaryopoietic changes (P<0.001) compared to the older donors. Female donors showed more dysgranulopoietic changes than male donors (P=0.025). The concordance rate between the 4 investigators was modest in dysgranulopoiesis but poor in dyserythropoiesis and dysmegakaryopoiesis. ConclusionsThe poor reliability of the 10% cut off was partly related to the proximity of the current criteria to the observed cut-off mean values of the normal population. These findings question the current WHO threshold of the 10% or over necessary for the percentage of cells manifesting dysplasia to be considered significant, and suggest that either a higher threshold would be more appropriate or different thresholds should be set for each lineage.Key words: dysplasia, hematopoiesis, cut off, significant, percentage, bone marrow donors.Citation: Parmentier S, Schetelig J, Lorenz K, Kramer M, Ireland R, Schuler U, Ordemann R, Rall G, Schaich M, Bornhäuser M, Ehninger G, and

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors

Parmentier¹,

Schetelig²,

Lorenz³

et al. 2011

Haematologica

View full text Add to dashboard Cite

show abstract

“…Autoimmunity against the erythroid lineage usually results in erythroblastopenia rather than in dyserythropoiesis: suppression of haematopoiesis by IgG autoantibodies has been demonstrated in patients with systemic lupus erythematosus ( Liu et al , 1995 ). Moreover, a few cases of steroid‐responsive dyserythropoiesis have been reported in association with lupus erythematosus and have been considered to be secondary to an autoimmune mechanism ( Jimenez‐Balderas et al , 1994 ; Kettaneh et al , 1998 ). Similarly, autoimmune myelodysplasia, regressive under immunosuppressive therapy, appears to be a clinical entity that probably results from an immune attack, directed against the haematopoietic precursor cells ( Miescher et al , 1991 ).…”

Section: Discussionmentioning

confidence: 99%

Dyserythropoiesis associated with a Fas‐deficient condition in childhood

et al. 2000

View full text Add to dashboard Cite

Defective lymphocyte apoptosis caused by mutations of the Fas gene can result in an autoimmune lymphoproliferative syndrome (ALPS) in humans. We report two cases of dyserythropoiesis associated with a Fas-deficient condition in childhood. In both cases, dyserythropoiesis predominated on the more mature erythroblasts, and was associated with a lymphoproliferative syndrome as well as with haemolytic anaemia, hypergammaglobulinaemia and the expansion of an unusual population of CD4- CD8- T cells that express the alpha/beta T-cell receptor. The regression of dyserythropoiesis under steroid therapy suggested that it resulted from an autoimmune mechanism, itself secondary to the lymphocyte Fas apoptosis deficiency. Fas-defective apoptosis may be a new aetiology for childhood dyserythropoiesis.

show abstract

“…Autoimmune hemolytic anemia has been reported in association with MDS [57][58][59]. Association of systemic lupus erythematosus and MDS has been reported [60][61][62].…”

Section: Miscellaneousmentioning

confidence: 99%

Myelodysplastic Syndrome and Autoimmune Disorders: Causal Relationship or Coincidence?

Newman¹,

Akhtari²,

Heidarian³

2019

Recent Developments in Myelodysplastic Syndromes

View full text Add to dashboard Cite

Myelodysplastic syndromes are heterogeneous group of clonal hematologic malignancies characterized by peripheral blood cytopenias secondary to the ineffective hematopoiesis. ADs are frequently reported in MDS, the incidence ranging from 10 to 30%, and particularly ADs are more frequently seen at CMML. ADs may prone patient to MDS, especially when immune suppressors such as azathioprine are used for the underlying AD. Both innate and adaptive immune systems, and different cytokines including interleukins, TNF-α, and C-X-C motif chemokine 10 (CXCL10) contribute in immune dysregulation of MDS. Vasculitis, seronegative rheumatoid arthritis, SLE, Behçet's disease, RP, and AIHA are just some of the ADs occurring concomitantly with MDS. Although hematopoietic growth factors are recommended by the American Society of Clinical Oncology (ASCO), it has been recognized from several case reports that treatment of the underlying MDS may resolve the associated autoimmune disorders. The heterogeneity and complexity of pathology, clinical manifestations, response to therapy, and prognosis of MDS and its immune dysregulation make the prognosis of MDS with autoimmune diseases a matter of debate. Better understanding of the immune dysregulation of MDS in the molecular level may help to design prospective, double blind clinical trials to find the best treatment options for autoimmune disorders associated with MDS.

show abstract

Acute Sideroblastic Anemia in Active Systemic Lupus Erythematosus

Cited by 14 publications

References 14 publications

Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors

Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors

Dyserythropoiesis associated with a Fas‐deficient condition in childhood

Myelodysplastic Syndrome and Autoimmune Disorders: Causal Relationship or Coincidence?

Contact Info

Product

Resources

About